ObjectiveTo observe the effectiveness and safety of anlotinib combined with docetaxel in the third-line treatment of advanced squamous cell lung carcinoma.

MethodsOne hundred patients with advanced squamous cell lung carcinoma were selected and divided into control group (n=44) and observation group (n=56) according to the random number table method.The control group was treated with dexamethasone and docetaxel, and the observation group was treated with anlotinib additionally on the basis of control group.The clinical efficacy, adverse reactions, survival and quality of life were compared between the two groups.

ResultsAfter treatment, there was no statistical difference in the objective remission rate, disease control rate, incidence of adverse reactions and mortality between the two groups (P>0.05).The overall survival time of control group and observation group was 10.21 months (95%CI:7.290-13.139) and 12.65 months (95%CI:10.588-14.712), respectively.After treatment, the scores of functional area and general health status of the two groups were higher than those before treatment (P < 0.05), and the scores of symptom area and cancer symptom were lower than those before treatment (P < 0.05);the scores of functional area and general health status in the observation group were significantly higher than those in control group (P < 0.01), and the scores of symptom area and cancer symptom in observation group were significantly lower than those in control group (P < 0.01).

ConclusionsThe combination of amlotinib hydrochloride and docetaxel in the third-line treatment of advanced squamous cell lung carcinoma can prolong survival time, improve quality of life, and not significantly increase adverse reactions of patients.